If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

According to Precedence Research, the global gRNA market size is expected to grow from USD 708.92 million in 2025 to nearly ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell leukemia.

A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond ...

Innovative therapy gives hope to patients whose blood cancer ‘seemed incurable’ ...

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Penn Medicine shows how sustained research investment drives innovation, economic growth, and global health breakthroughs.

Biomaterials have evolved from passive structural scaffolds to active intelligent systems that dynamically interact with the biological environment. Recent ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...